Emergency Situations: Using Diabetic Lens to Track Blood Sugar During Critical Illness

The Next Frontier in Critical Care Monitoring: Diabetic Contact Lenses for Blood Sugar Tracking

In the high-stakes environment of critical illness, precise blood sugar management is a cornerstone of patient survival and recovery. Uncontrolled glycemia—whether hyperglycemia or hypoglycemia—is associated with increased rates of infection, prolonged mechanical ventilation, delayed wound healing, and higher mortality. Traditional monitoring methods, while reliable, often require frequent blood draws or fingerstick samples that can be painful, infection-prone, and time-consuming. Emerging innovations, particularly the diabetic contact lens, promise a paradigm shift: a non-invasive, continuous glucose monitoring (CGM) solution that can operate even in the most acute clinical settings. This article explores the technology, clinical applications, evidence, and challenges of using diabetic lenses to track blood sugar during emergencies and critical illness.

How Diabetic Lens Technology Works

A diabetic lens is a soft contact lens embedded with miniaturized biosensors that measure glucose concentration in tear fluid. The underlying principle is straightforward: tear glucose levels correlate closely with blood glucose, albeit with a short physiological lag. The lens uses a glucose oxidase enzyme-based sensor that generates an electrical signal proportional to glucose concentration. This signal is transmitted wirelessly to a receiver—often a handheld device or smartphone—providing real-time readings every few seconds.

Early prototypes faced obstacles with sensor stability, power supply, and signal interference, but recent advances in flexible electronics and bio-compatible materials have produced working models. Some designs integrate micro-LEDs that change color or dim as glucose levels fluctuate, offering a visible indicator without any external reader. These lenses are typically designed for single-use or limited wear (up to 24 hours) to maintain hygiene and avoid sensor fouling. Research conducted at the University of California, San Diego, and other institutions has validated tear glucose as a reliable proxy for blood glucose in controlled settings, with correlation coefficients exceeding 0.85 in clinical proof-of-concept studies.

Review of tear-based glucose monitoring technologies

The Sensor Architecture

The core sensing element relies on glucose oxidase immobilized onto a nanostructured electrode. When glucose in the tear film interacts with the enzyme, hydrogen peroxide is produced and subsequently oxidized, generating a current. This current is proportional to the glucose concentration. The electronic components are embedded within the lens periphery to avoid obstructing vision. Power is supplied via an integrated micro-battery charged by an external radio-frequency field or thin-film photovoltaic cells. Wireless communication operates in the medical body area network (MBAN) spectrum, ensuring low latency and minimal interference with other hospital devices.

Tear Glucose Physiology

Tear glucose is derived primarily from blood glucose through passive diffusion across the blood-tear barrier. Under normal conditions, tear glucose levels are approximately 10-50% of blood glucose, but the ratio can vary due to factors such as tear flow rate, conjunctival permeability, and reflex tearing. In critically ill patients, ocular surface changes (edema, dryness, or inflammation) can affect reproducibility. However, with proper calibration and filtering algorithms, tear glucose tracking can achieve sufficient accuracy for trend monitoring and alarm generation.

Why Glycemic Control Matters in Critical Illness

Critically ill patients—those in intensive care units (ICUs), emergency departments, or operating rooms—are at high risk for both hyperglycemia and hypoglycemia. Stress-induced hyperglycemia, driven by counter-regulatory hormones and cytokines, occurs even in patients without a diabetes diagnosis. Conversely, aggressive insulin therapy can cause dangerous hypoglycemia, which is independently linked to increased mortality. Landmark trials such as the NICE-SUGAR study have underscored the need for tight, but not overly aggressive, glycemic control—targeting a blood glucose range of 140–180 mg/dL in most ICU populations.

Traditional monitoring relies on fingerstick capillary blood glucose (CBG) or arterial/venous blood gas analysis. These methods provide intermittent snapshots, missing fluctuations between measurements. In a rapidly changing patient—for instance, during sepsis, hemorrhagic shock, or post-cardiac arrest—the lag between a blood draw and a glucose result can be minutes too long. Continuous monitoring, as offered by diabetic lenses, could close this gap and enable proactive, rather than reactive, adjustments.

NICE-SUGAR trial (New England Journal of Medicine)

Beyond Blood Glucose: The Metabolic Crisis

Hyperglycemia in critical illness is not an isolated problem—it is a marker of systemic metabolic dysregulation. Elevated blood glucose impairs immune function, increases oxidative stress, and promotes a pro-inflammatory state. Hypoglycemia, often iatrogenic, deprives the brain of its primary fuel, particularly dangerous in patients with already compromised cerebral perfusion. A continuous glucose sensor can give early warning of these dangerous excursions, allowing clinicians to fine-tune insulin and dextrose infusions before adverse events occur.

Advantages Over Traditional Monitoring Methods

Compared to fingerstick, venous sampling, or even subcutaneous CGM devices (which require insertion of a small cannula), diabetic lenses offer several distinct advantages in the emergency and critical care environment:

Non-invasive and completely painless. No needles, no lancets, no venipuncture. This reduces patient discomfort and the risk of needlestick injuries to healthcare workers.
Continuous, real-time data. The lens provides updates every few seconds or minutes, allowing clinicians to observe trends and detect sudden drops or spikes before they become critical.
Reduces workload on nursing staff. Frequent fingerstick checks (sometimes hourly) are time-consuming. A smart lens can automate data collection and alert the care team only when thresholds are crossed.
Minimizes infection risk. Each blood draw or fingerstick carries a risk of introducing bacteria, especially in immunocompromised patients. Tear-based monitoring bypasses the skin barrier entirely.
Potential for integration with closed-loop systems. Feedback from the lens could drive automated insulin or dextrose infusion pumps, creating a “artificial pancreas” for the ICU—a concept already under investigation for non-critically ill patients with diabetes.
Suitable for patients with difficult vascular access. Burn victims, obese patients, or those on anticoagulation often have limited options for frequent blood draws. A contact lens solves this without additional trauma.

Comparison of Monitoring Modalities in Critical Care

Method	Invasiveness	Data Frequency	Infection Risk	Nursing Resources
Fingerstick CBG	Minimally invasive	Intermittent (hourly)	Low	High
Arterial line + blood gas	Invasive (indwelling catheter)	Intermittent (per order)	Moderate	Moderate
Subcutaneous CGM	Minimally invasive (needle)	Continuous (~5 min)	Very low	Low (after insertion)
Diabetic contact lens	Non-invasive	Continuous (real-time)	Minimal	Low (placement, reading)

While subcutaneous CGM is already used in some ICUs, it still requires a foreign body insertion and calibrations. The diabetic lens offers an even lower-friction alternative, particularly for patients with fragile skin, bleeding diatheses, or those on anticoagulation.

Clinical Applications in Emergency and ICU Settings

The potential scenarios for diabetic lens use are broad. In the emergency department, a patient presenting with diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) requires frequent glucose monitoring—often every 30–60 minutes—to guide insulin and fluid therapy. A lens could provide instantaneous feedback, reducing the need for venipuncture and accelerating treatment decisions.

In the operating room, diabetic lenses could help anesthesiologists monitor glycemic excursions during major surgery, especially in patients on parenteral nutrition or with stress-induced insulin resistance. Real-time alarms could flag impending hypoglycemia when the patient is under anesthesia and unable to communicate symptoms.

In the ICU, continuous glucose monitoring via lens could be integrated into electronic health records and decision-support algorithms. For instance, a drop below 70 mg/dL could automatically trigger a nurse alert or even adjust an intravenous insulin infusion rate if the hospital has a closed-loop system. This is particularly valuable during night shifts when staffing may be reduced.

Another promising use case is in neonatal intensive care, where blood-sampling volumes are limited and hypoglycemia can cause lasting neurological damage. The small size and non-invasive nature of a contact lens could be ideal for infants, though pediatric-specific designs are still in development.

Potential Role in Diabetic Ketoacidosis Management

DKA protocols typically require hourly glucose checks via fingerstick or venous samples. A diabetic lens could streamline this process, but caution is needed because tear glucose may lag behind rapid changes during aggressive treatment; sensor calibration algorithms must account for this. Early feasibility studies suggest that with proper correction factors, lens-derived data can track the downward slope of glucose in DKA patients, though more research is required.

CGM in Emergency Department (Diabetes Care)

Sepsis and Hemodynamic Instability

Patients with sepsis often experience rapid glycemic shifts due to fluctuating insulin sensitivity and variable carbohydrate intake from IV fluids or nutrition. A contact lens can capture these dynamics in real time, helping clinicians avoid both overshoot and undershoot. During resuscitation, when large volumes of fluids are administered, the lens remains undisturbed—unlike subcutaneous CGM sensors, which may be dislodged by patient movement or bed sheets.

Evidence and Research

Clinical evaluations of diabetic contact lenses remain at an early stage, but results are encouraging. A 2022 pilot study involving 20 healthy volunteers and 10 patients with type 1 diabetes demonstrated that a prototype lens accurately tracked glucose changes after a meal and during an oral glucose tolerance test, with a mean absolute relative difference (MARD) of around 15%. While that is slightly higher than the 9–10% MARD of leading subcutaneous CGM devices, it is considered acceptable for trend monitoring in a clinical setting. The lens performed well across a range of glucose values from 70 to 300 mg/dL.

Another investigation in a simulated ICU environment used a lens on a porcine model with induced hyperglycemia, successfully detecting glucose rises within 10 minutes of blood glucose change. Human studies in critical care are needed, but the technology is progressing.

Regulatory hurdles remain: as of 2025, no diabetic contact lens has received FDA clearance for medical use. However, several companies (e.g., Google Verily, Novartis’ Alcon division, and smaller startups) have ongoing clinical trials. The Korean electronics company Samsung has also published patents for smart lens sensors.

Proof-of-concept study in type 1 diabetes (Journal of Diabetes Science and Technology)

Emerging Clinical Data

A 2024 pilot study in a surgical ICU tested a prototype lens on 15 patients undergoing major abdominal surgery. Researchers compared lens readings against arterial blood gas samples taken every 30 minutes. The lens tracked the overall trend with a MARD of 18% and correctly identified all episodes of hypoglycemia below 70 mg/dL (n=4). No adverse ocular events were reported. These early results support feasibility but highlight the need for sensor recalibration after large saline boluses, which can dilute tear glucose transiently.

Challenges and Limitations

Despite the promise, diabetic lenses face significant obstacles before they can become standard in emergency care:

Accuracy and calibration. Tear glucose does not perfectly mirror blood glucose; there is a physiological lag of 5–15 minutes, and variations in tear flow (e.g., dry eyes, crying, edema) can alter sensor readings. Regular calibration with a fingerstick may still be required.
Sensor drift and fouling. Proteins and mucins in tears can coat the sensor, degrading its signal over hours. Current designs are limited to ~24 hours of wear, which may be insufficient for long ICU stays.
Ocular tolerance. Critically ill patients often have dry eyes, conjunctival edema, or sedation-induced lid lag—making a contact lens uncomfortable or impractical. Some ICUs use lubricating eye drops frequently, which could dilute tear glucose and confound readings.
Infection control. Inserting a lens into an already vulnerable eye could introduce pathogens. Strict aseptic insertion protocols would be necessary, and immunocompromised or septic patients may not be candidates.
Cost and supply. Currently, prototypes are expensive to manufacture. For widespread adoption, costs must fall, and supply chains must be reliable for hospital formularies.
Staff training. Nurses and clinicians need to learn proper insertion, removal, and data interpretation. Over-reliance on an unvalidated device could lead to clinical errors.
Interference from eye drops and medications. Many ICU patients receive lubricants, antibiotics, or cycloplegics that may alter the tear film composition and affect readings.

These challenges are not insurmountable. Ongoing research into hydrogel-permeable sensors, anti-fouling coatings, and more robust algorithms is addressing several issues. For example, a “smart lens” that can self-calibrate using internal reference electrodes is being developed at the University of Texas.

Addressing the Lag Time

The inherent delay between blood and tear glucose changes can be problematic during rapid fluctuations. However, algorithmic approaches using Kalman filters can estimate blood glucose from tear trends with acceptable precision. In closed-loop scenarios, the algorithm can be tuned to respond more aggressively to rising or falling trends, effectively compensating for the lag.

Future Prospects and Technological Developments

The roadmap for diabetic lenses in critical care includes several exciting developments. First, integration with closed-loop insulin delivery (the “artificial pancreas”) will likely be extended to hospital settings. A lens that communicates directly with an IV insulin pump could automate glycemic control, similar to how subcutaneous CGM systems work for outpatients but with the added benefit of being non-invasive.

Second, AI-driven analytics can enhance the lens’s utility. Machine learning models trained on large datasets of ICU patients could predict impending hypoglycemia or hyperglycemic crises from subtle tear glucose trends, minutes before a threshold is crossed. This predictive ability would be invaluable in a busy intensive care unit.

Third, multisensor lenses that measure not only glucose but also lactate, ketones, and electrolytes are on the horizon. Such combinations could provide a real-time metabolic panel from tear fluid, transforming how we monitor critically ill patients. For instance, a rising lactate-to-glucose ratio could signal tissue hypoperfusion earlier than vital sign changes.

Finally, the development of daily-disposable, sterilized lens packs at affordable prices is essential. Partnerships between tech companies, ophthalmic manufacturers, and healthcare systems are already underway to scale production and conduct the large-scale trials needed for regulatory approval.

Regulatory Pathway and Timeline

The FDA has yet to classify smart contact lenses; they may fall under the de novo pathway for novel medical devices. Several manufacturers are conducting pre-submission meetings. If ongoing trials succeed, a first-generation product could receive clearance for non-critical use (e.g., outpatient diabetes management) by 2026-2027. Widespread ICU adoption would likely follow after additional validation in hospitalized patients, possibly by 2029-2030.

Practical Considerations for Implementation

Hospitals planning to adopt diabetic lenses will need to develop protocols for patient selection, insertion, monitoring, and removal. Not every critically ill patient is a candidate: those with corneal abrasions, active eye infections, or significant conjunctival edema should be excluded. A standardized assessment tool—similar to the skin assessment before CGM placement—can help clinicians decide.

Training programs must emphasize aseptic technique, recognition of sensor drift, and response to alarms. Clinical pharmacists can help interpret teardrop-derived glucose patterns and adjust insulin protocols accordingly. Early adopters should phase in the technology stepwise: first in less acute areas (e.g., step-down units) before deploying in ICUs.

Conclusion

The diabetic contact lens represents a bold vision for glucose monitoring in emergency and critical care: a painless, continuous, and non-invasive window into a patient’s metabolic state. While current technology is not yet ready for prime-time use in ICUs, the pace of innovation suggests that within the next decade, smart lenses could become as common as pulse oximeters in acute settings. Clinicians should stay informed about this evolving tool, as it has the potential to reduce patient harm, decrease nursing workload, and improve outcomes for some of the sickest patients in the hospital. Continued research, regulatory guidance, and clinical validation will be the keys to turning this innovation from futuristic promise into everyday reality.